¼¼°èÀÇ ÀǾàǰ Çãºê ¹× ȯÀÚ ¾×¼¼½º Áö¿ø ¼­ºñ½º ½ÃÀå
Pharma HUB and Patient Access Support Services
»óǰÄÚµå : 1777423
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 284 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÀǾàǰ Çãºê ¹× ȯÀÚ ¾×¼¼½º Áö¿ø ¼­ºñ½º ½ÃÀåÀº 2030³â±îÁö 52¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 32¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀǾàǰ Çãºê ¹× ȯÀÚ ¾×¼¼½º Áö¿ø ¼­ºñ½º ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 8.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 52¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÇÁ·Î±×·¥ µî·ÏÀº CAGR 6.4%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 12¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Ä¡·á ³×ºñ°ÔÀÌÅÍ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 10.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8¾ï 7,160¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR12.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀǾàǰ Çãºê ¹× ȯÀÚ ¾×¼¼½º Áö¿ø ¼­ºñ½º ½ÃÀåÀº 2024³â¿¡ 8¾ï 7,160¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 11¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 12.6%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 4.4%¿Í 7.9%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.5%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ ÀǾàǰ HUB ¹× ȯÀÚ ¾×¼¼½º Áö¿ø ¼­ºñ½º ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀǾàǰ Çãºê ¹× ȯÀÚ ¾×¼¼½º Áö¿ø ¼­ºñ½º´Â ¹«¾ùÀ̸ç, ȯÀÚ¿¡°Ô ¾î¶² ÀÌÁ¡À» °¡Á®´Ù Áִ°¡?

ÀǾàǰ Çãºê ¹× ȯÀÚ ¾×¼¼½º Áö¿ø ¼­ºñ½º´Â ȯÀÚ°¡ ÇÊ¿äÇÑ ÀǾàǰÀ» ±¸Çϰí, º¹ÀâÇÑ ÀÇ·á ½Ã½ºÅÛÀ» ÀÌ¿ëÇϰí, Ä¡·á ¿ä¹ýÀ» °ü¸®ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÏ´Â Àü¹® ¼­ºñ½ºÀ̸ç, ƯÈ÷ °íºñ¿ë, Ư¼ö Áúȯ, ¸¸¼º ÁúȯÀ» À§ÇÑ ¼­ºñ½ºÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼­ºñ½º¿¡´Â ȯÀÚ°¡ ó¹æµÈ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖµµ·Ï ȯÀÚ ±³À°, ÀçÁ¤ Áö¿ø ÇÁ·Î±×·¥, º¸Çè ¾È³», ÈĹæ Áö¿ø µîÀÌ Æ÷ÇԵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. Pharma HUB´Â ⱸÀÇ Á᫐ ¿ªÇÒÀ» ¼öÇàÇϸç, º¸Çè È®ÀÎ, º»Àκδã±Ý Áö¿ø, ¾àǰ ºÐ¹è, Á¢±Ù¼º Àå¾Ö ´ëÀÀ µî Ä¡·áÀÇ ¸ðµç Ãø¸éÀ» Á¶Á¤ÇÏ¿© ȯÀÚ¿¡°Ô °³º°È­µÈ Áö¿øÀ» Á¦°øÇÕ´Ï´Ù.

ÀÌ·¯ÇÑ ¼­ºñ½º´Â °í°¡ÀÇ Àü¹®ÀǾàǰÀ̳ª º¹ÀâÇÑ Áúȯ, Èñ±ÍÁúȯ Ä¡·áÁ¦¸¦ ÇÊ¿ä·Î Çϴ ȯÀڵ鿡°Ô ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. Pharma HUB´Â ȯÀÚ°¡ Àû½Ã¿¡ ÀǾàǰÀ» ¹ÞÀ» ¼ö ÀÖµµ·Ï Áö¿øÇÏ´Â ÇÑÆí, ȯÀÚ°¡ ÀúÃà ÇÁ·Î±×·¥À̳ª º¸Çè Áö¿øÀ» ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µî Ä¡·áÀÇ °æÁ¦Àû ºÎ´ãÀ» °ü¸®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ Á¢±Ù ¹× Áö¿ø ¼­ºñ½º´Â °£È£»ç ÇÖ¶óÀÎ, Ä¡·á ±³À°, ȯÀÚ°¡ Ä¡·á ¿ä¹ýÀ» ÁؼöÇÒ ¼ö ÀÖµµ·Ï Áö¼ÓÀûÀÎ Áö¿ø µîÀÇ ¸®¼Ò½º¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ È¯ÀÚ Ä¡·á¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Á¢±Ù ¹æ½ÄÀº ȯÀÚÀÇ ºÎ´ãÀ» ÁÙÀ̰í, Ä¡·á °á°ú¸¦ °³¼±Çϸç, ȯÀÚ°¡ Ä¡·á ¿©Á¤ µ¿¾È ÇÊ¿äÇÑ Áö¿øÀ» ¹ÞÀ» ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

ÀǾàǰ Çãºê ¹× ȯÀÚ ¾×¼¼½º Áö¿ø ¼­ºñ½º ½ÃÀåÀÌ È®´ëµÇ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

Á¦¾à Çãºê ¹× ȯÀÚ Á¢±Ù Áö¿ø ¼­ºñ½º ½ÃÀåÀº ÇコÄÉ¾î ½Ã½ºÅÛÀÇ º¹À⼺, °³ÀÎÈ­µÈ ȯÀÚ Á᫐ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Àü¹® ÀǾàǰ »ç¿ë Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â ÀÇ·á ȯ°æÀÇ º¹À⼺À¸·Î ÀÎÇØ ȯÀÚ°¡ º¸Çè ¿ä°ÇÀ» Á¶Á¤Çϰí, ÀǾàǰÀ» ±¸Çϰí, Ä¡·á °èȹÀ» °ü¸®ÇÏ´Â °ÍÀÌ ´õ ¾î·Á¿öÁ³½À´Ï´Ù´Â °ÍÀÔ´Ï´Ù. ¸¸¼ºÁúȯ°ú Èñ±ÍÁúȯÀÇ È®»êÀ¸·Î ÀÎÇØ °í°¡ÀÇ Àü¹®ÀǾàǰÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹¾ÆÁö¸é¼­ ÀÌ °úÁ¤À» °£¼ÒÈ­Çϰí Ä¡·áÀÇ À庮À» ³·Ãߴ ȯÀÚ Á¢±Ù¼º ¼­ºñ½ºÀÇ Çʿ伺ÀÌ ±× ¾î´À ¶§º¸´Ù ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

½ÃÀå È®´ë¿¡ ±â¿©ÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ ¿äÀÎÀº °³º°È­µÈ Á¾ÇÕÀûÀÎ Äɾ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. ȯÀÚ°¡ ¿øÇÏ´Â °ÍÀº ¾à¸¸ ÀÖ´Â °ÍÀÌ ¾Æ´Õ´Ï´Ù. Ä¡·áÀÇ ¿©Á¤À» ÅëÇØ ¾È³», ÀçÁ¤Àû Áö¿ø, Á¤½ÅÀû ÁöÁö°¡ ÇÊ¿äÇÕ´Ï´Ù. Pharma HUB¿Í ȯÀÚ Á¢±Ù Áö¿ø ¼­ºñ½º´Â »ç·Ê°ü¸® ¼­ºñ½º, Ä¡·á ¼øÀÀµµ ÇÁ·Î±×·¥, °³º°È­µÈ °æÁ¦Àû Áö¿ø µî ¸ÂÃãÇü ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ´ÏÁî¿¡ ºÎÀÀÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á Á¦°ø¾÷ü, Á¦¾à»ç, ÁöºÒÀÚ°¡ ó¹æÀüÀ» ³Ñ¾î¼± ȯÀÚ Áö¿øÀÇ Á߿伺À» ÀνÄÇϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.

¶ÇÇÑ, Ư¼ö ÀǾàǰÀÇ ºÎ»óµµ ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ÃËÁøÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦³ª À¯ÀüÀÚ Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ Æ¯¼ö ÀǾàǰÀº º¹ÀâÇÑ ÁúȯÀ̳ª Èñ±ÍÁúȯÀÇ Ä¡·á¸¦ À§ÇØ Ã³¹æµÇ´Â °æ¿ì°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀǾàǰÀº °í°¡À̸ç, Àü¹®ÀûÀÎ Åõ¾à°ú Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ °æ¿ì°¡ ¸¹½À´Ï´Ù. Pharma HUB´Â º¸Çè Àû¿ë ¹üÀ§ ÀÌÇØ, ÀçÁ¤Àû Áö¿ø È®º¸, ¾à¹° Àü´Þ Á¶Á¤ µî ȯÀÚ°¡ ÀÌ·¯ÇÑ ÀǾàǰÀ» ±¸ÇÏ´Â µ¥ µû¸£´Â º¹ÀâÇÑ ¹®Á¦¸¦ ÇØ°áÇϵµ·Ï µ½½À´Ï´Ù. Ư¼ö ÀǾàǰ ½ÃÀåÀÌ °è¼Ó È®´ëµÊ¿¡ µû¶ó, ȯÀÚµéÀÌ ÀÌ·¯ÇÑ Ä¡·á¿¡ ½±°Ô Á¢±ÙÇÏ°í °ü¸®ÇÒ ¼ö ÀÖ´Â ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Á¦¾àÇãºê¿Í ȯÀÚ Á¢±Ù Áö¿ø ¼­ºñ½ºÀÇ ¹Ì·¡¸¦ Á¿ìÇÒ ÁÖ¿ä µ¿ÇâÀº?

Á¦¾à Çãºê ¹× ȯÀÚ Á¢±Ù Áö¿ø ¼­ºñ½º ½ÃÀåÀÇ ¹Ì·¡´Â µðÁöÅÐ Çコ ÅøÀÇ ÅëÇÕ ¹ßÀü, °¡Ä¡ ±â¹Ý ÀÇ·áÀÇ ºÎ»ó, °Ç°­ÀÇ »çȸÀû °áÁ¤ ¿äÀο¡ ´ëÇÑ °ü½É Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ Æ®·»µå¿¡ ÀÇÇØ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. °¡Àå Å« Æ®·»µå Áß Çϳª´Â ȯÀÚ Á¢±Ù Áö¿ø ¼­ºñ½º¿¡ µðÁöÅÐ Çコ ÅøÀ» ÅëÇÕÇÏ´Â °ÍÀÔ´Ï´Ù. ¸ð¹ÙÀÏ ¾Û, ¿ø°Ý ÀÇ·á »ó´ã, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ µîÀ» Æ÷ÇÔÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ȯÀÚ°¡ Ä¡·á ¿ä¹ýÀ» ´õ Àß °ü¸®ÇÏ°í °Ç°­ °ü¸®¿¡ ´õ Àû±ØÀûÀ¸·Î Âü¿©ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ·¯ÇÑ µðÁöÅÐ Ç÷§ÆûÀ» ÅëÇØ Pharma HUB´Â ½Ç½Ã°£ Áö¿øÀ» Á¦°øÇϰí, ȯÀÚÀÇ ÁøÇà »óȲÀ» ÃßÀûÇϰí, °³º°È­µÈ °³ÀÔÀ» Á¦°øÇÔÀ¸·Î½á ȯÀڵ鿡°Ô º¸´Ù ÇÕ¸®ÀûÀ̰í È¿À²ÀûÀÎ ÀÇ·á ÇÁ·Î¼¼½º¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.

°¡Ä¡ ±â¹Ý Äɾî´Â Pharma HUB¿Í ȯÀÚ Á¢±Ù Áö¿ø ¼­ºñ½ºÀÇ ¹Ì·¡¸¦ Çü¼ºÇÏ´Â ¶Ç ´Ù¸¥ Áß¿äÇÑ Æ®·»µåÀÔ´Ï´Ù. ÇコÄÉ¾î ¾÷°è´Â ¼­ºñ½ºÀÇ ¾çº¸´Ù ÁúÀ» ¿ì¼±½ÃÇÏ´Â ¸ðµ¨·Î ÀüȯÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ȯÀÚ°¡ Ä¡·á °èȹÀ» Áö۰í, ÇÊ¿äÇÑ ÀǾàǰÀ» ±¸Çϰí, ´õ ³ªÀº °Ç°­ »óŸ¦ ´Þ¼ºÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â µ¥ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ¼øÀÀµµ¸¦ Áö¿øÇϰí, °æÁ¦Àû Áö¿øÀ» Á¦°øÇϸç, Áö¼ÓÀûÀÎ »ç·Ê °ü¸®¸¦ Á¦°øÇϴ ȯÀÚ Á¢±Ù ¼­ºñ½º´Â ÀÌ·¯ÇÑ °¡Ä¡ ±â¹Ý Ä¡·á ¸ðµ¨¿¡ ºÎÇÕÇϸç, ȯÀÚ°¡ ÀÚ½ÅÀÇ »óŸ¦ È¿°úÀûÀ¸·Î °ü¸®ÇÏ´Â µ¥ ÇÊ¿äÇÑ µµ±¸¸¦ Á¦°ø¹ÞÀ» ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿Í Á¦¾àȸ»ç°¡ Ä¡·á ¼øÀÀµµ¿Í ȯÀÚ ¸¸Á·µµ Çâ»ó¿¡ ÁýÁßÇϰí ÀÖ´Â °¡¿îµ¥, ÀÌ·¯ÇÑ Ãß¼¼´Â ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¦¾àÇãºê¿Í ȯÀÚ Á¢±Ù Áö¿ø ¼­ºñ½ºÀÇ ¹Ì·¡¸¦ Á¿ìÇÒ ¶Ç ´Ù¸¥ Æ®·»µå´Â °Ç°­ÀÇ »çȸÀû °áÁ¤¿äÀÎ(SDOH)¿¡ ´ëÇÑ °ü½ÉÀÌ ÁýÁߵǰí ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ÀÌ´Â »çȸ°æÁ¦Àû ÁöÀ§, ±³À°, ÁÖº¯ ȯ°æ, ÀÇ·á ¼­ºñ½º Á¢±Ù¼º µî °Ç°­ »óÅ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ºñÀÇ·áÀû ¿äÀÎÀ» ¸»ÇÕ´Ï´Ù. Á¦¾à»ç HUB ¹× ȯÀÚ Á¢±Ù ¼­ºñ½º¿¡¼­´Â ±³Åë, À½½Ä, »çȸÀû Áö¿ø ½Ã½ºÅÛ¿¡ ´ëÇÑ Á¢±ÙÀ» Áö¿øÇÏ´Â Áö¿ø ÇÁ·Î±×·¥À» Á¦°øÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¿äÀεéÀ» ÇØ°áÇÏ´Â ¼Ö·ç¼ÇÀ» µµÀÔÇÏ´Â °ÍÀ» Á¡Á¡ ´õ ¸¹ÀÌ °í·ÁÇϰí ÀÖ½À´Ï´Ù. SDOH¸¦ ÇØ°áÇÔÀ¸·Î½á ÀÌ·¯ÇÑ ¼­ºñ½º´Â ¹è°æ¿¡ °ü°è¾øÀÌ ¸ðµç ȯÀÚ°¡ ó¹æµÈ Ä¡·á¿¡ Á¢±ÙÇϰí À̸¦ ÁؼöÇÏ´Â µ¥ ÇÊ¿äÇÑ ÀÚ¿ø°ú Áö¿øÀ» È®º¸ÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¦¾à Çãºê ¹× ȯÀÚ Á¢±Ù Áö¿ø ¼­ºñ½º ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

Á¦¾à Çãºê ¹× ȯÀÚ Á¢±Ù Áö¿ø ¼­ºñ½º ½ÃÀåÀÇ ¼ºÀåÀº ÀÇ·á º¸ÇèÀÇ º¹À⼺, Àü¹® ÀǾàǰÀÇ È®´ë, ȯÀÚ Áß½É Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â º¸Çè Á¦µµ¿Í »óȯ Á¦µµÀÇ º¹À⼺ÀÔ´Ï´Ù. ÇコÄɾî Ç÷£ÀÌ º¹ÀâÇØÁö°í Ư¼ö ÀǾàǰ¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ȯÀÚµéÀº Á¾Á¾ ÀÚ±âºÎ´ã±Ý, ó¹æ Á¦ÇÑ, º¸Çè Àû¿ë ÀÚ°Ý µî º¹ÀâÇÑ »óȲÀ» ÇìÃijª°¡¾ß ÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. Pharma HUB´Â ȯÀÚÀÇ º¸Çè Àû¿ë¿¡ ´ëÇÑ ÀÌÇØ¸¦ µ½°í, ½ÂÀÎ ÀýÂ÷¸¦ ÃËÁøÇϸç, ȯÀÚ°¡ °úµµÇÑ °æÁ¦Àû ºÎ´ã ¾øÀÌ ÀǾàǰÀ» ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇÔÀ¸·Î½á ÀÌ °úÁ¤À» °£¼ÒÈ­ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áö¿øÀº ȯÀÚÀÇ Ä¡·á Á¢±Ù¼ºÀ» °³¼±Çϰí Ä¡·á ¼øÀÀµµ¸¦ ³ôÀÌ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

Ư¼ö ¾àǰÀÇ »ç¿ë È®´ëµµ ½ÃÀå ¼ºÀåÀÇ Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. Àü¹®ÀǾàǰÀº º¹ÀâÇÑ ¸¸¼ºÁúȯÀ̳ª Èñ±ÍÁúȯÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â °æ¿ì°¡ ¸¹À¸¸ç, ÀÌ·¯ÇÑ ÀǾàǰÀº °¡°ÝÀÌ ¸Å¿ì ºñ½Ò ¼ö ÀÖ½À´Ï´Ù. Pharma HUB´Â ȯÀÚ°¡ º´À» °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀÎ ÀǾàǰ¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Á¦°øÇϱâ À§ÇØ ÀçÁ¤Àû Áö¿ø°ú º¸Çè °¡ÀÔ Å½»öÀ» Á¦°øÇÕ´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦, À¯ÀüÀÚ Ä¡·áÁ¦ ¹× ±âŸ °í°¡ Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó, źźÇÑ È¯ÀÚ Á¢±Ù¼º Áö¿ø ¼­ºñ½ºÀÇ Çʿ伺Àº ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, ȯÀÚ Á᫐ ÀÇ·á·ÎÀÇ ÀüȯÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀÔ´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ °³ÀÎÈ­µÈ ÀüÀÎÀû Ä¡·á¸¦ ¿ì¼±½ÃÇÔ¿¡ µû¶ó, ȯÀÚ°¡ Ä¡·á ¿©Á¤ µ¿¾È Á¾ÇÕÀûÀÎ Áö¿øÀ» ¹ÞÀ» ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÌ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â ¾àǰ Á¦°ø»Ó¸¸ ¾Æ´Ï¶ó ȯÀÚ°¡ Á÷¸éÇÑ Á¤½ÅÀû, °æÁ¦Àû, ¹°·ùÀû ¹®Á¦¿¡ ´ëÇÑ ´ëÀÀµµ Æ÷ÇԵ˴ϴÙ. Pharma HUB¿Í ȯÀÚ Á¢±Ù ¼­ºñ½º´Â ÀÌ·¯ÇÑ Ãß¼¼ÀÇ ÃÖÀü¼±¿¡ ÀÖÀ¸¸ç, ȯÀÚÀÇ ´Ù¾çÇÑ ¿ä±¸¿¡ ´ëÀÀÇÏ´Â ¸ÂÃãÇü Á¾ÇÕ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ´õ ¸¹Àº ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿Í Á¦¾àȸ»ç°¡ °á°ú °³¼±¿¡ ÀÖ¾î ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀÇ °¡Ä¡¸¦ ÀνÄÇÔ¿¡ µû¶ó, ÀÌ·¯ÇÑ ¼­ºñ½º ½ÃÀåÀº °è¼Ó È®´ëµÉ °ÍÀ̸ç, ȯÀÚ°¡ º¹ÀâÇÑ Çö´ë ÀǷḦ ±Øº¹ÇÏ´Â µ¥ ÇÊ¿äÇÑ ÀÚ¿øÀ» È®º¸ÇÒ ¼ö ÀÖ°Ô µÉ °ÍÀÔ´Ï´Ù.

ºÎ¹®

¼­ºñ½º À¯Çü(ÇÁ·Î±×·¥ µî·Ï, Ä¡·á ³»ºñ°ÔÀÌÅÍ, ȯ±Þ ¼­ºñ½º/°æÁ¦¼º ¼­ºñ½º, ÀÓ»ó ±³À°ÀÚ, Àü¹® ¾à±¹/Á¶Á¦ Á¶Á¤, ±âŸ); ¼­ºñ½º Á¦°ø À¯Çü(ÅëÇÕ ¼­ºñ½º, µ¶¸³Çü ¼­ºñ½º)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pharma HUB and Patient Access Support Services Market to Reach US$5.2 Billion by 2030

The global market for Pharma HUB and Patient Access Support Services estimated at US$3.2 Billion in the year 2024, is expected to reach US$5.2 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Program Enrollment, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Treatment Navigators segment is estimated at 10.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$871.6 Million While China is Forecast to Grow at 12.6% CAGR

The Pharma HUB and Patient Access Support Services market in the U.S. is estimated at US$871.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 12.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.4% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Pharma HUB and Patient Access Support Service Market - Key Trends & Drivers Summarized

What Are Pharma HUB and Patient Access Support Services and How Do They Benefit Patients?

Pharma HUB and Patient Access Support Services are specialized services that help patients access necessary medications, navigate complex healthcare systems, and provide assistance with managing treatment regimens, especially for high-cost, specialty, or chronic conditions. These services often include patient education, financial assistance programs, insurance navigation, and logistical support to ensure patients can receive their prescribed therapies. Pharma HUBs serve as central points of contact, offering personalized support to patients by coordinating all aspects of their treatment journey, including insurance verification, copay assistance, distribution of medication, and addressing barriers to access.

These services are particularly beneficial for patients who require expensive specialty drugs or therapies for complex or rare diseases. Pharma HUBs help ensure that patients receive their medications in a timely manner, while also assisting in managing the financial burden of treatments, including helping patients access savings programs or insurance support. Additionally, Patient Access Support Services offer resources such as nurse hotlines, treatment education, and ongoing support to help patients adhere to their therapy regimens. This holistic approach to patient care reduces the strain on patients, improves treatment outcomes, and ensures that they receive the necessary support throughout their treatment journey.

Why Is the Pharma HUB and Patient Access Support Services Market Expanding?

The Pharma HUB and Patient Access Support Services market is expanding due to several factors, including the rising complexity of healthcare systems, the growing demand for personalized and patient-centric services, and the increasing use of specialty medications. One of the main drivers of market growth is the increasing complexity of the healthcare landscape, which makes it more difficult for patients to navigate insurance requirements, obtain medications, and manage their treatment plans. With the growing prevalence of chronic and rare diseases, many of which require expensive specialty medications, the need for patient access services that can simplify this process and reduce barriers to care is more pressing than ever.

Another key factor contributing to the market’s expansion is the increasing demand for personalized and comprehensive care. Patients are seeking more than just medications-they need guidance, financial assistance, and emotional support throughout their treatment journey. Pharma HUBs and Patient Access Support Services cater to this need by offering tailored solutions, including case management services, treatment adherence programs, and personalized financial assistance. This shift towards more patient-centric approaches has driven the growth of these services as healthcare providers, pharmaceutical companies, and payers recognize the importance of supporting patients beyond the prescription.

The rise of specialty medications is also a significant driver of growth in this market. Specialty drugs, including biologics and gene therapies, are increasingly being prescribed to treat complex or rare diseases. These medications are often high-cost and may require specialized administration or ongoing monitoring. Pharma HUBs help patients navigate the complexities associated with accessing these drugs, such as understanding insurance coverage, securing financial assistance, and coordinating the delivery of medications. As the market for specialty drugs continues to grow, so does the demand for services that make it easier for patients to access and manage these treatments.

What Key Trends Are Shaping the Future of Pharma HUB and Patient Access Support Services?

Several key trends are shaping the future of the Pharma HUB and Patient Access Support Services market, including the increasing integration of digital health tools, the rise of value-based care, and the growing focus on addressing social determinants of health. One of the most significant trends is the integration of digital health tools into patient access support services. These tools, including mobile apps, telemedicine consultations, and remote patient monitoring, allow patients to better manage their treatment regimens and engage more actively in their healthcare. Through these digital platforms, Pharma HUBs can provide real-time support, track patient progress, and offer personalized interventions, making the healthcare process more streamlined and efficient for patients.

Value-based care is another key trend shaping the future of Pharma HUBs and Patient Access Support Services. The healthcare industry is increasingly moving toward a model where the quality of care is prioritized over the volume of services provided. This shift has led to greater focus on ensuring patients adhere to their treatment plans, have access to the medications they need, and achieve better health outcomes. Patient access services that support adherence, provide financial assistance, and offer ongoing case management align with this value-based care model, ensuring that patients receive the necessary tools to manage their conditions effectively. This trend is expected to drive further growth in the market as healthcare providers and pharmaceutical companies focus on improving treatment adherence and patient satisfaction.

Another trend influencing the future of Pharma HUB and Patient Access Support Services is the growing focus on addressing social determinants of health (SDOH). These are the non-medical factors that impact health outcomes, such as socioeconomic status, education, neighborhood, and access to healthcare. Pharma HUBs and patient access services are increasingly looking to incorporate solutions that address these factors by offering support programs that help with access to transportation, food, or social support systems. By addressing SDOH, these services can ensure that all patients, regardless of their background, have the resources and support they need to access and adhere to their prescribed treatments.

What Are the Key Drivers of Growth in the Pharma HUB and Patient Access Support Services Market?

The growth of the Pharma HUB and Patient Access Support Services market is driven by several factors, including the increasing complexity of healthcare coverage, the expansion of specialty medications, and the rising demand for patient-centered care. One of the key drivers is the increasing complexity of insurance and reimbursement systems. As healthcare plans become more intricate and specialty medications grow in prominence, patients often find themselves navigating a complicated landscape of copays, formulary restrictions, and insurance eligibility. Pharma HUBs streamline this process by helping patients understand their insurance coverage, facilitating approval processes, and ensuring that they receive their medications without undue financial burden. This support plays a critical role in improving patient access to care and ensuring treatment adherence.

The growing use of specialty medications is another key driver of market growth. Specialty drugs are often used to treat complex, chronic, or rare conditions, and these medications can be prohibitively expensive. Pharma HUBs offer assistance with securing financial aid, insurance navigation, and providing access to these medications, which are crucial in helping patients manage their conditions. As the demand for biologics, gene therapies, and other high-cost treatments continues to rise, the need for robust patient access support services will only increase.

Finally, the increasing shift towards patient-centered care is a significant driver in the market. As healthcare systems prioritize personalized and holistic care, there is greater emphasis on ensuring that patients receive comprehensive support throughout their treatment journey. This includes not only providing medications but also addressing emotional, financial, and logistical challenges patients face. Pharma HUBs and patient access services are at the forefront of this trend, offering tailored, comprehensive solutions that meet the diverse needs of patients. As more healthcare providers and pharmaceutical companies recognize the value of this approach in improving outcomes, the market for these services will continue to grow, ensuring patients have the resources they need to navigate the complexities of modern healthcare.

SCOPE OF STUDY:

The report analyzes the Pharma HUB and Patient Access Support Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service Type (Program Enrollment, Treatment Navigators, Reimbursement Services / Affordability Services, Clinical Educator, Coordination of Specialty Pharmacy / Dispensing, Others); Service Delivery Type (Integrated Services, Standalone Services)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â